Navigation Links
BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
Date:8/13/2008

ur late-stage clinical trials:

- MAESTRO-01: A pivotal phase II/III trial for secondary progressive

MS (SPMS) patients in Canada and Europe.

- MAESTRO-02: An open-label safety extension study to MAESTRO-01.

- MAESTRO-03: A pivotal phase III trial for SPMS patients in the United

States.

- MINDSET-01: A phase II trial for relapsing-remitting MS (RRMS)

patients in Europe.

MAESTRO-01 is a multi-center, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of dirucotide (MBP8298) in patients with secondary progressive MS. The study is being conducted at 47 sites across Canada and nine countries in Europe and includes 611 patients being administered either dirucotide (MBP8298) or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease, as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes. Time to disease progression in patients with other HLA-DR types will be assessed separately as an exploratory arm of the same study.

About Dirucotide (MBP8298)

--------------------------

Dirucotide (MBP8298) is a synthetic peptide that consists of 17 amino acids having a sequence identical to that of a portion of human myelin basic protein (MBP). Dirucotide is being developed for the potential treatment of multiple sclerosis (MS), an autoimmune disease caused by immune attack against normal components of the central nervous system. The sequence of dirucotide is associated with the autoimmune process in MS patients with certain immune response genes (HLA types DR2 and/or DR4); MS patients having these genes represent 65 to 75 percent of all MS patients.

The drug's apparent mechanism of action is the induction or restoration of immun
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical Announces Second Quarter 2008 Results
2. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
3. BioMS Medical to present at BMO Healthcare Conference
4. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medical to present at Jefferies Healthcare Conference
6. BioMS Medical to present at 2008 BIO International Convention
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medical announces first quarter 2008 results
9. BioMs Medical to present at TIDES(R) Conference
10. BioMS Medical to present at Rodman and Renshaw Global Healthcare Conference
11. BioMS Medical Provides Update On Pipeline Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ANGELES , July 6, 2015 ImmunoCellular ... establishment of an agreement with Novella Clinical ... ICT-107 in patients with newly diagnosed glioblastoma. Novella is ... trial services to small to mid-sized oncology companies. The ... sites in the US, Europe ...
(Date:7/3/2015)... , July 3, 2015 /PRNewswire/ ... hakea verkossa osoitteessa  http://www.openinnovationinscience.at ... Innovation in Science" -jatkokoulutusohjelmaan 22.7.2015 ... Gesellschaftin (LBG) tekemän, kansainvälisiä tutkijoita ... terveystieteiden kaksi suurinta haastetta ovat ...
(Date:7/3/2015)... 3, 2015 Forskare ... 2015 på  http://www.openinnovationinscience.at till det återkommande ... som hålls i Wien ... med internationella forskare och vetenskapsmän som genomfördes ... två största utmaningar bristen på incitament för ...
(Date:7/3/2015)... , July 3, 2015 ... 22. september 2015 på  http://www.openinnovationinscience.at om ... der finder sted i Wien ... undersøgelse af internationale forskere og videnskabsmænd foretaget ... to største udfordringer for sundhedsvidenskaben manglen på ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3
... 5 Replidyne, Inc.,(Nasdaq: RDYN ) today announced its ... 30, 2008., Replidyne reported a net loss of $18.7 ... loss per basic and diluted common share of $0.69,per share, ... basic,common share or $1.65 per common share on a fully ...
... to Curb Unsafe Sex and Drug, Use ... Response, MEXICO CITY, Aug. 5 In a ... calls on global leaders to aggressively,expand HIV prevention programs ... use. Citing hundreds of clinical trials and,observational studies, the ...
... Nexavar Net Sales increase 107% over Second Quarter 2007, ... ONXX ) today reported its financial results,for the ... reported net income,of $4.5 million, or $0.08 per diluted ... net loss of $10.8 million, or $0.22 per diluted ...
Cached Biology Technology:Replidyne Announces Second Quarter 2008 Results From Operations 2Replidyne Announces Second Quarter 2008 Results From Operations 3Replidyne Announces Second Quarter 2008 Results From Operations 4Replidyne Announces Second Quarter 2008 Results From Operations 5Replidyne Announces Second Quarter 2008 Results From Operations 6Replidyne Announces Second Quarter 2008 Results From Operations 7Leading AIDS Experts Urge Greater Focus on Behavior-Change Programs to Prevent HIV 2Leading AIDS Experts Urge Greater Focus on Behavior-Change Programs to Prevent HIV 3Leading AIDS Experts Urge Greater Focus on Behavior-Change Programs to Prevent HIV 4Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 2Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 3Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 4Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 5Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 6Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 7Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 8Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 9Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results 10
(Date:6/23/2015)... BEACH GARDENS, Fla. , June 23, ... multi-factor identity management and authentication solutions, today announced ... Altus strong, multi-factor authentication solution.  The enhancements ... of use of the DigitalPersona Altus platform ... biometric reader compatibility. In today,s ...
(Date:6/18/2015)... June 18, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market announces that its Wocket® ... on "Money on the Mark", scheduled to air on WABC ... June 20 th . The broadcast air- ... 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira ...
(Date:6/17/2015)... Germany , June 17, 2015 ... QIA) today launched new Investigator ® STR assay kits ... the United States . The new genetic fingerprint ... genomic markers (short tandem repeats or STRs) for DNA matching. ... the quality of DNA in each sample, a novel QIAGEN ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... to Critical Data with MobileCop(R) ... ... International Inc.,(OTC Bulletin Board: BKYI), a leader in finger-based biometric,identification and ... Baltimore (MD) Police Department ("BPD"),for additional licenses of BIO-key,s MobileCop software ...
... DURHAM, N.H. Researchers at the University of New ... structure that confers anti-inflammatory activity to a ... of autoimmune diseases like lupus or rheumatoid arthritis. The ... Science, was led by immunologist Jeffrey Ravetch of Rockefeller ...
... American Society for Microbiology (ASM) has endorsed the ... human, animal, and environmental health and seeks to ... areas for the health and well-being of all ... Health Initiative are consistent with the ASM mission ...
Cached Biology News:BIO-key(R) Receives $335,000 Contract Award From Baltimore Police 2BIO-key(R) Receives $335,000 Contract Award From Baltimore Police 3Sugar linkage could lead to better treatment for autoimmune diseases 2American Society for Microbiology supports 'One Health' initiative 2
Quinolinate phosphoribosyltransferase...
ICC Diluent Buffer 250 ml...
This antibody is specific for human J-chain as defined by ELISA assay using purified human immunoglobulin fragments as solid phase target antigen....
...
Biology Products: